Castle Biosciences has delivered a strong 83.6% gain over the past three years, yet its valuation checks send a more measured message, with the stock screening as undervalued on some metrics and less clear on others. That mix, combined with recent share price softness this year, leaves investors weighing how much of the story is already in the price.
- The 83.6% return over three years means anyone who stayed invested through the volatility has been rewarded, which raises the bar for fresh upside from here.
- The recent publication on the DecisionDx-SCC test can support confidence in the medical utility of Castle Biosciences' assays, while execution risk around broader clinical adoption and reimbursement may still cap how much value the market is willing to assign.
- The stock earns a mixed valuation verdict, with 4 of 6 checks suggesting it leans cheap rather than clearly expensive.
The issue now is whether Castle Biosciences' current share price fairly reflects those strengths and uncertainties or still leaves a margin that long term holders may find attractive.
Look beyond Castle Biosciences and stress test your thesis against 33 high quality undervalued stocks, focusing on companies that combine solid fundamentals with valuations that the market has not fully rewarded yet.
Is Castle Biosciences Still Cheap on Sales?
P/S fits Castle Biosciences because revenue is still the main yardstick investors use when earnings remain volatile and reinvestment is heavy.
On this lens, Castle Biosciences trades on a P/S of 2.8x. That sits above the broader Healthcare sector average of about 1.4x and above a peer group closer to 0.8x. The fair P/S ratio implied by Simply Wall St’s model is 3.1x, which reflects what investors might expect to pay given the business profile and risk.
The gap between the current 2.8x and the 3.1x fair ratio suggests the stock screens undervalued on sales, even after the positive DecisionDx-SCC data drew attention to the testing portfolio. For anyone already focused on cash flow and clinical traction, this P/S check points to a market that is not fully pricing in those fundamentals.
On the preferred P/S multiple, Castle Biosciences looks undervalued relative to the level the model flags as fair.
See what the numbers say about this price — find out in our valuation breakdown.
The Castle Biosciences Narrative: What Would Justify Today's Price?
Castle Biosciences’ valuation puzzle sets up the role of Simply Wall St Narratives, which map out what future growth, profitability and earnings patterns would need to look like for the shares to be worth meaningfully more or materially less than today. These Narratives sit on Simply Wall St’s Community page for anyone who wants to see the reasoning behind the numbers. Where a single multiple or model outputs one figure, these explanations spell out the future that figure relies on so you can later check whether reality stays aligned.
One of the top community narratives on Castle Biosciences: 27% undervalued
"Progress toward broader reimbursement, including the ongoing reconsideration process for DecisionDx-SCC and the pursuit of new LCD policies for pipeline tests, has the potential to materially improve average selling prices and margin structure, driving stronger earnings and cash flow leverage over time..."
Read one of the top narratives on Castle Biosciences
Do you think there's more to the story for Castle Biosciences? Head over to our Community to see what others are saying!
The Bottom Line
Castle Biosciences screens as undervalued on its preferred market multiple, yet the broader valuation checks remain mixed rather than emphatically cheap. That split puts the focus on whether clinical adoption and reimbursement progress eventually pull the P/S closer to the model’s fair level or keep a lid on any re rating. The real debate from here is simple. Either the discount reflects lingering execution and reimbursement risk, or it marks a gap between the current share price and the business Castle Biosciences is building.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com